– USA, NY – Lucid Diagnostics Inc. a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM) today announced the appointment of prominent global industry executive Aster Angagaw to its Board of Directors.
“I am delighted to welcome Aster Angagaw to Lucid’s Board of Directors. She brings decades of business experience as a chief executive, global transformation leader, and public company director, with deep longstanding roots in the global healthcare sector. Her experience working with large integrated healthcare delivery networks and knowledge of medical technology supply chain systems will be particularly valuable to our growing commercial activities,” said Executive Chairman, Dr. Lishan Aklog.
He added: “With Ms. Angagaw joining recent appointees, Stanley Lapidus and Dr. Jacque Sokolov, Lucid has a world-class board of directors with the diverse skills and experience to provide critical guidance as we seek to execute on our ambitious long-term growth strategy.”
Ms. Angagaw will serve on the Audit and Nominating Committees.
About Aster Angagaw
Ms. Angagaw currently serves as a member of the Board of Directors of Owens & Minor Inc. (NYSE: OMI), a leading healthcare logistics company providing vital supply chain services to healthcare providers and manufacturers of healthcare products, from disposable medical supplies to devices and implants. She recently served as President of ServiceMaster Brands, the $2.6 billion revenue franchise services division of ServiceMaster Global Holdings Inc. (NYSE: SERV), a leading provider of essential services to residential and commercial customers.
Last year, Ms. Angagaw guided the sale of the division to a private equity firm for $1.6 billion. Before ServiceMaster, she served in a series of senior executive roles at Sodexo SA (EPA: SW), a Paris-headquartered multinational diversified services company with 440,000 employees and over $20 billion in revenue. Over 23 years at Sodexo, she had a successful record of accomplishment in operations, strategy and business development, organizational transformation, and customer retention. She rose to become CEO, Healthcare North America, overseeing 6,000 employees providing services as well as facilities and clinical technology management to top-rated hospitals and children’s oncology centers in the US and Canada.
Notable prior roles at Sodexo included serving as a member of its Healthcare Global Executive Committee, SVP, Global Head of Sales and Business Development, responsible for directing business development and creating a unified global sales organization for the global Healthcare segment, and Group VP for Global Transformation, where she helped lead a transition from country-specific business units to a unified global model.
Ms. Angagaw has received numerous honors and has been named multiple times to Black Enterprise magazine’s list of the Most Influential Black Executives in Corporate America and Most Powerful Women in Business, as well as Savoy magazine’s list of the Top Influential Women in Corporate America. She also received the Diversity Leadership Council’s Leadership Excellence Award. In 2020, Aster was awarded the distinguished 400 Award from 400 years of African American History Commission.
She serves on the advisory board of the Women in Business Collaborative, an alliance of businesswomen’s organizations working together to achieve equal position, pay, and power for all women in business. She is also a member of the Executive Leadership Council, a national organization comprising current and former Black CEOs and senior executives at Fortune 1000 and Global 500 companies, which has worked to build an inclusive business leadership pipeline and seeks to open channels of opportunity for the development of Black executives to positively impact business and our communities.
“I have spent my career focused on mission-oriented organizational transformation and strategic operational execution, much of it while navigating the complexities of the healthcare industry,” I “I am very excited to join this rapidly-growing and innovative medical technology company with a clear vision and mission to save lives through widespread precancer screening using cutting-edge technologies. I look forward to working with Dr. Aklog, Lucid’s strong management team, and my esteemed board colleagues. Together we have a unique opportunity to execute this important mission.”
Ms. Angagaw received her bachelor’s degree in Organizational Management from Eastern University in Pennsylvania and an M.B.A. from the Fox School of Business at Temple University. She is also a graduate of the Harvard Business School Advanced Management Program.
About Lucid Diagnostics
Lucid Diagnostics Inc. markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure Esophageal Ablation Device with Caldus Technology.
About PAVmed
PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities.
Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Its Minimally Invasive Interventions division markets its CarpX Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy (PortIO Implantable Intraosseous Vascular Access Device and NextFlo Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support).
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.